Developing ovarian cancer stem cell models: laying the pipeline from discovery to clinical intervention

Hdl Handle:
http://hdl.handle.net/10147/337579
Title:
Developing ovarian cancer stem cell models: laying the pipeline from discovery to clinical intervention
Authors:
Ffrench, Brendan; Gasch, Claudia; O’Leary, John J; Gallagher, Michael F
Citation:
Ffrench, B. et al., 2014. Developing ovarian cancer stem cell models: laying the pipeline from discovery to clinical intervention. Molecular Cancer, 13 (1) pp 262
Issue Date:
11-Dec-2014
URI:
http://dx.doi.org/10.1186/1476-4598-13-262; http://hdl.handle.net/10147/337579
Abstract:
Abstract Despite decades of research, ovarian cancer is still associated with unacceptably high mortality rates, which must be addressed by novel therapeutic approaches. One avenue through which this may be achieved is targeting of tumor-initiating ‘Cancer Stem Cells’ (CSCs). CSCs are sufficient to generate primary and recurrent disease through extensive rounds of asymmetric division, which maintain the CSC pool while producing the tissues that form the bulk of the tumor. CSCs thrive in the harsh tumor niche, are generally refractory to therapeutic intervention and closely-linked to the Epithelial-Mesenchymal Transition process, which facilitates invasion and metastasis. While it is well-accepted that CSC-targeting must be assessed as a novel therapeutic avenue, few ovarian CSC models have been developed due to perceived and actual difficulties associated with the process of ‘CSC Discovery’. In this article we review contemporary approaches to CSC Discovery and argue that this process should start with an understanding of the specific challenges associated with clinical intervention, laying the pipeline backwards towards CSC Discovery. Such an approach would expedite the bridging of the gap between laboratory isolation and clinical targeting of ovarian CSCs.
Item Type:
Article
Language:
en
Keywords:
OVARIAN CANCER
Local subject classification:
STEM CELLS

Full metadata record

DC FieldValue Language
dc.contributor.authorFfrench, Brendanen_GB
dc.contributor.authorGasch, Claudiaen_GB
dc.contributor.authorO’Leary, John Jen_GB
dc.contributor.authorGallagher, Michael Fen_GB
dc.date.accessioned2014-12-23T12:42:20Z-
dc.date.available2014-12-23T12:42:20Z-
dc.date.issued2014-12-11-
dc.identifier.citationFfrench, B. et al., 2014. Developing ovarian cancer stem cell models: laying the pipeline from discovery to clinical intervention. Molecular Cancer, 13 (1) pp 262en_GB
dc.identifier.urihttp://dx.doi.org/10.1186/1476-4598-13-262-
dc.identifier.urihttp://hdl.handle.net/10147/337579-
dc.description.abstractAbstract Despite decades of research, ovarian cancer is still associated with unacceptably high mortality rates, which must be addressed by novel therapeutic approaches. One avenue through which this may be achieved is targeting of tumor-initiating ‘Cancer Stem Cells’ (CSCs). CSCs are sufficient to generate primary and recurrent disease through extensive rounds of asymmetric division, which maintain the CSC pool while producing the tissues that form the bulk of the tumor. CSCs thrive in the harsh tumor niche, are generally refractory to therapeutic intervention and closely-linked to the Epithelial-Mesenchymal Transition process, which facilitates invasion and metastasis. While it is well-accepted that CSC-targeting must be assessed as a novel therapeutic avenue, few ovarian CSC models have been developed due to perceived and actual difficulties associated with the process of ‘CSC Discovery’. In this article we review contemporary approaches to CSC Discovery and argue that this process should start with an understanding of the specific challenges associated with clinical intervention, laying the pipeline backwards towards CSC Discovery. Such an approach would expedite the bridging of the gap between laboratory isolation and clinical targeting of ovarian CSCs.-
dc.language.isoenen
dc.subjectOVARIAN CANCERen_GB
dc.subject.otherSTEM CELLSen_GB
dc.titleDeveloping ovarian cancer stem cell models: laying the pipeline from discovery to clinical interventionen_GB
dc.typeArticleen
dc.language.rfc3066en-
dc.rights.holderBrendan Ffrench et al.; licensee BioMed Central Ltd.-
dc.description.statusPeer Reviewed-
dc.date.updated2014-12-18T12:03:14Z-
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.